Market Overview:
The global non-opioid pain treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of chronic pain, rising awareness about non-opioid pain treatments, and the launch of new products. The medical cannabis treatment segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the growing acceptance of medical cannabis as a treatment for various conditions, including chronic pain. The capsaicin-derived treatment segment is also expected to grow at a high rate during the forecast period owing to its efficacy in treating various types of chronic pain.
Product Definition:
Non-opioid pain treatments are medications or other therapies that can help relieve pain without using opioids. They are important because they can help people avoid or reduce their use of opioids, which can lead to addiction and other problems. Non-opioid treatments include over-the-counter medications such as ibuprofen and aspirin, as well as prescription medications and therapies such as physical therapy and acupuncture.
Medical Cannabis Treatment:
Medical cannabis treatment is the use of marijuana, also known as cannabis or hemp plant, for medical purposes. The main reason people give a damn about using it medically is because it's been proven to help patients deal with chronic pain better than any other medication available in the market. Medical cannabis has been used for thousands of years and was only made illegal in the last 30 years or so.
Capsaicin-derived Treatment:
Capsaicin-derived treatments are used for the treatment of chronic non-opioid pain. Capsaicin is a naturally occurring substance in hot peppers that produces a burning sensation when applied to skin. The amount of capsaicin in hot peppers varies according to variety and degree of ripeness.
Application Insights:
The orthopedic and musculoskeletal pain segment dominated the global non-opioid pain treatment market in 2017. This is due to factors such as high prevalence of arthritis, growing acceptance of medical cannabis for treating various arthritic conditions, increasing availability of opioid alternatives with less side effects and a more favorable cost-benefit ratio.
According to the Arthritis Foundation, around 54 million people in America are affected by arthritis. In addition, as per the U.S Department of Health & Human Services; every year around 675 thousand people die due to complications arising from arthritic diseases in America alone which indicates a huge potential market waiting to be tapped by pharmaceutical companies and other competitors operating in this space.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to rising awareness about chronic and acute pain, availability of treatment alternatives, supportive government initiatives, and high healthcare expenditure levels in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing cases of chronic pain due to injuries or accidents as well as neuropathic pain caused by diabetes or other conditions such as shingles and HIV/AIDS that are not responding adequately to other treatments; these factors are driving demand for non-opioid therapies in this region. In addition, favorable regulatory reforms for cannabis use may also spur market growth during the estimated time frame.
Growth Factors:
- Increasing incidence of chronic pain: The global prevalence of chronic pain is estimated to be around 20%, and it is projected to increase to 30% by 2030. This will create a large pool of patients who would need treatment for their chronic pain, providing a growth opportunity for the non-opioid pain treatment market.
- Rising awareness about the dangers of opioids: There has been a growing awareness about the dangers of opioids in recent years, with reports highlighting how they are often overprescribed and lead to addiction and other health problems. This has led many people to seek alternative treatments for their pain, such as non-opioid medications or therapies.
- Advances in technology: The development of new technologies has led to the introduction of novel non-opioid treatments for pain, such as nerve stimulation devices and targeted drug delivery systems. These technologies are helping to improve the efficacy and safety profile of these treatments, thereby driving their adoption rates higher.
- Growing focus on personalized medicine: There is an increasing focus on personalized medicine nowadays, with healthcare providers looking at ways to individualize treatment plans based on each patient’s specific needs and preferences. This is particularly relevant in cases where there are multiple possible treatment options available, such as with non-opioid therapies for chronic pain management .This trend is likely to help boost adoption rates for these therapies in the coming years .5) Rise In geriatric population :The global population
Scope Of The Report
Report Attributes
Report Details
Report Title
Non-Opioid Pain Treatment Market Research Report
By Type
Medical Cannabis Treatment, Capsaicin-derived Treatment, Menthol-containing Treatment, Omega 3 fatty acid-containing Treatment, Botulinum Toxins, Non-Opioid Pain Treatmen
By Application
Orthopaedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Others
By Companies
Allergan PLC, Canopy Growth, Medical Marijuana Inc., Panag Pharma Inc., Tilray, Aphria Inc., Bedrocan, Cara Therapeutics, Centrexion Therapeutics, CHT Medical, Cronos Group, GW Pharmaceuticals, Medropharm Gmbh, US Worldmeds LLC, Non-Opioid Pain Treatmen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Non-Opioid Pain Treatment Market Report Segments:
The global Non-Opioid Pain Treatment market is segmented on the basis of:
Types
Medical Cannabis Treatment, Capsaicin-derived Treatment, Menthol-containing Treatment, Omega 3 fatty acid-containing Treatment, Botulinum Toxins, Non-Opioid Pain Treatmen
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Orthopaedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan PLC
- Canopy Growth
- Medical Marijuana Inc.
- Panag Pharma Inc.
- Tilray
- Aphria Inc.
- Bedrocan
- Cara Therapeutics
- Centrexion Therapeutics
- CHT Medical
- Cronos Group
- GW Pharmaceuticals
- Medropharm Gmbh
- US Worldmeds LLC
- Non-Opioid Pain Treatmen
Highlights of The Non-Opioid Pain Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medical Cannabis Treatment
- Capsaicin-derived Treatment
- Menthol-containing Treatment
- Omega 3 fatty acid-containing Treatment
- Botulinum Toxins
- Non-Opioid Pain Treatmen
- By Application:
- Orthopaedic and Musculoskeletal Pain
- Neuropathic Pain
- Cancer Pain
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Non-Opioid Pain Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Non-opioid pain treatment is a type of treatment that does not involve the use of opioids. Non-opioid treatments can include medications, therapies, and surgery.
Some of the major players in the non-opioid pain treatment market are Allergan PLC, Canopy Growth, Medical Marijuana Inc., Panag Pharma Inc., Tilray, Aphria Inc., Bedrocan, Cara Therapeutics, Centrexion Therapeutics, CHT Medical, Cronos Group, GW Pharmaceuticals, Medropharm Gmbh, US Worldmeds LLC, Non-Opioid Pain Treatmen.
The non-opioid pain treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Non-Opioid Pain Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Non-Opioid Pain Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Non-Opioid Pain Treatment Market - Supply Chain
4.5. Global Non-Opioid Pain Treatment Market Forecast
4.5.1. Non-Opioid Pain Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Non-Opioid Pain Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Non-Opioid Pain Treatment Market Absolute $ Opportunity
5. Global Non-Opioid Pain Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Non-Opioid Pain Treatment Market Size and Volume Forecast by Type
5.3.1. Medical Cannabis Treatment
5.3.2. Capsaicin-derived Treatment
5.3.3. Menthol-containing Treatment
5.3.4. Omega 3 fatty acid-containing Treatment
5.3.5. Botulinum Toxins
5.3.6. Non-Opioid Pain Treatmen
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Non-Opioid Pain Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Non-Opioid Pain Treatment Market Size and Volume Forecast by Application
6.3.1. Orthopaedic and Musculoskeletal Pain
6.3.2. Neuropathic Pain
6.3.3. Cancer Pain
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Non-Opioid Pain Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Non-Opioid Pain Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Non-Opioid Pain Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Non-Opioid Pain Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Non-Opioid Pain Treatment Demand Share Forecast, 2019-2026
9. North America Non-Opioid Pain Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Non-Opioid Pain Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Non-Opioid Pain Treatment Market Size and Volume Forecast by Application
9.4.1. Orthopaedic and Musculoskeletal Pain
9.4.2. Neuropathic Pain
9.4.3. Cancer Pain
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Non-Opioid Pain Treatment Market Size and Volume Forecast by Type
9.7.1. Medical Cannabis Treatment
9.7.2. Capsaicin-derived Treatment
9.7.3. Menthol-containing Treatment
9.7.4. Omega 3 fatty acid-containing Treatment
9.7.5. Botulinum Toxins
9.7.6. Non-Opioid Pain Treatmen
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Non-Opioid Pain Treatment Demand Share Forecast, 2019-2026
10. Latin America Non-Opioid Pain Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Non-Opioid Pain Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Non-Opioid Pain Treatment Market Size and Volume Forecast by Application
10.4.1. Orthopaedic and Musculoskeletal Pain
10.4.2. Neuropathic Pain
10.4.3. Cancer Pain
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Non-Opioid Pain Treatment Market Size and Volume Forecast by Type
10.7.1. Medical Cannabis Treatment
10.7.2. Capsaicin-derived Treatment
10.7.3. Menthol-containing Treatment
10.7.4. Omega 3 fatty acid-containing Treatment
10.7.5. Botulinum Toxins
10.7.6. Non-Opioid Pain Treatmen
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Non-Opioid Pain Treatment Demand Share Forecast, 2019-2026
11. Europe Non-Opioid Pain Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Non-Opioid Pain Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Non-Opioid Pain Treatment Market Size and Volume Forecast by Application
11.4.1. Orthopaedic and Musculoskeletal Pain
11.4.2. Neuropathic Pain
11.4.3. Cancer Pain
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Non-Opioid Pain Treatment Market Size and Volume Forecast by Type
11.7.1. Medical Cannabis Treatment
11.7.2. Capsaicin-derived Treatment
11.7.3. Mentholcontaining Treatment
11.7.4. Omega 3 fatty acid-containing Treatment
11.7.5. Botulinum Toxins
11.7.6. Non-Opioid Pain Treatmen
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Non-Opioid Pain Treatment Demand Share, 2019-2026
12. Asia Pacific Non-Opioid Pain Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Non-Opioid Pain Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Non-Opioid Pain Treatment Market Size and Volume Forecast by Application
12.4.1. Orthopaedic and Musculoskeletal Pain
12.4.2. Neuropathic Pain
12.4.3. Cancer Pain
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Non-Opioid Pain Treatment Market Size and Volume Forecast by Type
12.7.1. Medical Cannabis Treatment
12.7.2. Capsaicin-derived Treatment
12.7.3. Menthol-containing Treatment
12.7.4. Omega 3 fatty acid-containing Treatment
12.7.5. Botulinum Toxins
12.7.6. Non-Opioid Pain Treatmen
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Non-Opioid Pain Treatment Demand Share, 2019-2026
13. Middle East & Africa Non-Opioid Pain Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Non-Opioid Pain Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Non-Opioid Pain Treatment Market Size and Volume Forecast by Application
13.4.1. Orthopaedic and Musculoskeletal Pain
13.4.2. Neuropathic Pain
13.4.3. Cancer Pain
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Non-Opioid Pain Treatment Market Size and Volume Forecast by Type
13.7.1. Medical Cannabis Treatment
13.7.2. Capsaicin-derived Treatment
13.7.3. Menthol-containing Treatment
13.7.4. Omega 3 fatty acid-containing Treatment
13.7.5. Botulinum Toxins
13.7.6. Non-Opioid Pain Treatmen
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Non-Opioid Pain Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Non-Opioid Pain Treatment Market: Market Share Analysis
14.2. Non-Opioid Pain Treatment Distributors and Customers
14.3. Non-Opioid Pain Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan PLC
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Canopy Growth
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Medical Marijuana Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Panag Pharma Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Tilray
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Aphria Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bedrocan
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Cara Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Centrexion Therapeutics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CHT Medical
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Cronos Group
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. GW Pharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Medropharm Gmbh
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. US Worldmeds LLC
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Non-Opioid Pain Treatmen
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
